Physician profile
Maribeth Knight
NPI 1083681365
$6,340.05
in general payments reported to CMS, 2019-2025
42 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,161 · 2020: $173 · 2021: $479 · 2022: $1,063 · 2023: $1,079 · 2024: $1,221 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,418.54 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $613.10 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $555.56 | 2019-2025 | |
| Lilly USA, LLC | $506.09 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $401.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $336.09 | 2019-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $328.77 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $327.72 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $237.81 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.65 | 2024-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $130.39 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.23 | 2019-2024 | Xifaxan |
| Abbott Laboratories | $124.68 | 2021-2023 | Freestyle Libre 2 |
| Exact Sciences Corporation | $99.09 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $91.12 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.